Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Use of Molecular Genetic Analyses in Danish Routine Newborn Screening

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Including classical galactosaemia in the expanded newborn screening panel using tandem mass spectrometry for galactose-1-phosphate

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genetic disease is a common cause of bilateral childhood cataract in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A novel homoplasmic mt-tRNAGlu m.14701C>T variant presenting with a partially reversible infantile respiratory chain deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Quantitative Muscle MRI and Clinical Findings in Women With Pathogenic Dystrophin Gene Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Myopathy can be a key phenotype of membrin (GOSR2) deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Historically, the analyses used for newborn screening (NBS) were biochemical, but increasingly, molecular genetic analyses are being introduced in the workflow. We describe the application of molecular genetic analyses in the Danish NBS programme and show that second-tier molecular genetic testing is useful to reduce the false positive rate while simultaneously providing information about the precise molecular genetic variant and thus informing therapeutic strategy and easing providing information to parents. When molecular genetic analyses are applied as second-tier testing, valuable functional data from biochemical methods are available and in our view, such targeted NGS technology should be implemented when possible in the NBS workflow. First-tier NGS technology may be a promising future possibility for disorders without a reliable biomarker and as a general approach to increase the adaptability of NBS for a broader range of genetic diseases, which is important in the current landscape of quickly evolving new therapeutic possibilities. However, studies on feasibility, sensitivity, and specificity are needed as well as more insight into what views the general population has towards using genetic analyses in NBS. This may be sensitive to some and could have potentially negative consequences for the NBS programme.

Original languageEnglish
Article number50
JournalInternational Journal of Neonatal Screening
Volume7
Issue number3
ISSN2409-515X
DOIs
Publication statusPublished - Sep 2021

    Research areas

  • First-tier test, Neonatal screening, Newborn screening, Next generation sequencing, Second-tier test, Tandem mass spectrometry

ID: 67847683